Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Biologics Bill Clears Senate Cmte. With Stronger Language On Exclusivity Cap

This article was originally published in The Pink Sheet Daily

Executive Summary

Generic firms remain concerned that innovators would be able to "evergreen" their products through minor changes.

You may also be interested in...



Follow-On Biologics Legislation Could Reach Senate Floor By Year End

Design of patent protection, exclusivity and interchangeability provisions remains potential roadblock.

Follow-On Biologics Legislation Could Reach Senate Floor By Year End

Design of patent protection, exclusivity and interchangeability provisions remains potential roadblock.

Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon

Abraxis BioScience and Biocon have signed a licensing agreement that gives the Los Angeles firm the right to develop a biosimilar of granulocyte-colony stimulating factor in North America and the European Union, the companies announced July 19

Related Content

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel